

**SYNTHESIS, CHARACTERIZATION, ANTIMICROBIAL
AND MOLECULAR DOCKING STUDIES OF 1,3-
THIAZOLE DERIVATIVES**

BY

ISWATUN HASANAH BINTI ABDULLAH RIPAIN

**A thesis submitted in fulfilment of the requirement for the
degree of Doctor of Philosophy (Biosciences)**

**Kulliyyah of Science
International Islamic University Malaysia**

JANUARY 2021

ABSTRACT

There is growing urge to develop treatment systems to cure the diseases and one of the main options is drug development. Heterocyclic thiazole emerges as one of the most frequently reported in those fields. Since thiazole derivatives have been recognized in various biologically active agents, two series of thiazole derivatives which were 5-acetyl-4-methyl-1,3-thiazole (Series A; **T1A-T17A**) and 4,5-dimethyl-1,3-thiazole (Series B; **T1B-T17B**) were synthesized and characterized *via* ^1H and ^{13}C NMR, FTIR, UV-Vis and EI-MS. In IR analysis, all synthesized compounds exhibited important absorption bands. The data of UV analysis confirmed the presence of several chromophores which contributed in formation of electronic transition of $\pi \rightarrow \pi^*$ and $n \rightarrow \pi^*$ in the molecules. All resonances can be observed at expected regions in ^1H and ^{13}C NMR analysis. Mass spectra of all compounds showed acceptable m/z values which is in accordance with their theoretical molecular mass. In order to investigate the potential of compounds as antimicrobial agents, screening and *in-vitro* assays were applied. In disc diffusion test, all compounds in Series A inhibited the tested microbial strains with inhibition zone of 7.0 – 18.5 mm. In Series B, maximum inhibition zone is 16.3 mm. Based on this preliminary screening, ten newly synthesized compounds from Series A which contain substituted phenyl ring at position 2 of thiazole ring which are **T3A**, **T4A**, **T5A**, **T7A**, **T8A**, **T10A**, **T11A**, **T12A**, **T15A** and **T16A** were selected for further *in-vitro* assays. The MIC values revealed that all the selected compounds showing remarkable antimicrobial activity against both bacterial strains and fungus with **T3A**, **T4A**, **T5A** and **T7A** exhibited highest MIC value of 1.25 mg/mL towards *B. cereus*. The MBC assay indicated that all compounds demonstrating highest mortality properties towards *K. pneumoniae* with concentration of 10.0 mg/mL. The result of all combinations from synergistic effect between antibiotic and compound showed major antagonism and indifferent effects but a synergistic effect was observed in **T4A**, **T7A**, **T10A**, **T11A**, **T12A** and **T16A** compounds in combination with Tetracycline with FICI values of 0.2-0.3 against *E. coli*. Compound **T4A** was the most active compound with significant killing ability towards all tested microbes by showing the lowest number of colonies survived after 30 minutes at range of 13×10^2 - 43×10^2 CFU/mL followed by **T7A** and **T5A** at range of 17×10^2 - 48×10^2 and 13×10^2 - 51×10^2 CFU/mL respectively. **T4A** showed highest percentage of CV uptake towards *E. coli* and *S. flexneri* with percentage of 77.7% and 83.1%, respectively. Leakage determination of nucleic acids (UV₂₆₀) and protein (UV₂₈₀) absorbing materials showed **T4A** and **T7A** showed promising results with highest absorbance values of OD₂₆₀ were recorded at 1.07 and 0.98 against *E. coli* while, OD₂₈₀ were recorded at 1.00 and 0.98 towards *B. subtilis* at concentration of 4×MIC. All synthesized compounds of both series were subjected to *in silico* molecular docking screenings towards GlcN-6-P synthase as the target enzyme. The results revealed the significant binding energy values of **T4A**, **T7A** and **T5A** which are in agreement with antimicrobial results with -7.73, -7.32 and -7.31 kcal/mol respectively.

خلاصة البحث

دوافع متزايدة لتطوير أنظمة علاجية للأمراض، وأحد الخيارات الرئيسية هو تطوير الأدوية. يعتبر الثيازول الحلقي غير المتجانس من أكثر المركبات التي تم الإبلاغ عنها في هذه المجالات. منذ بداية التعرف على مشتقات الثيازول في العديد من المواد النشطة بيولوجيا تم توليف سلسلتين من مشتقات الثيازول، وهي: 5-أسيتيل-4-ميثيل-1,3-ثيازول (السلسلة **A**: T17A-T1A) و 4,5-ثنائي ميثيل-1,3-ثيازول (السلسلة **B**: T17B-T1B) وتمييزها من خلال الرنين المغناطيسي النووي ل H^1 و C^{13} (NMR)، وتحويل فورييه للطيف بالأشعة تحت الحمراء (FTIR)، ومطابقة الأشعة المرئية وفوق البنفسجية (UV-Vis)، و EI-MS. في تحليل الأشعة تحت الحمراء أظهرت جميع المركبات التي تم توليفها نطاقات امتصاص مهمة. أكدت بيانات تحليل UV-MS وجود العديد من الكروموفورات التي ساهمت في تشكيل الانتقال الإلكتروني ل $\pi \rightarrow \pi^*$ و $n \rightarrow \pi^*$ في الجزيئات، وبالإمكان ملاحظة جميع الرنات في المناطق المتوقعة في تحليل الرنين المغناطيسي النووي ل H^1 و C^{13} . أظهرت أطراف الكتلة لجميع المركبات قيم m/z مقبولة والتي توافقت مع كتلها الجزيئية النظرية. من أجل التحقيق في إمكانيات المركبات كمواد مضادة للميكروبات، تم تطبيق فحوصات مسحية وفحوصات مخبرية خارج الجسم الحي تجاه سلالات. في اختبار انتشار الأقراص، ثبتت جميع المركبات في السلسلة **A** السلالات البكتيرية المختبرة بمنطقة تثبيط بلغت 7.0 - 18.5 مم. في السلسلة **B**، بلغ الحد الأقصى لمنطقة التثبيط 16.3 مم. استناداً إلى هذا الفحص الأولي، تم اختيار عشرة مركبات من السلسلة **A** المولفة حديثاً والمحتوية على حلقة فينيل مستبدلة في الموضع 2 من حلقة الثيازول، وهي **T3A**، **T4A**، **T5A**، **T7A**، **T8A**، **T10A**، **T11A**، **T12A**، **T15A** و **T16A** لمزيد من الاختبارات خارج الجسم الحي. أظهرت قيم التركيز الأدنى للتثبيط (MIC) أن جميع المركبات المختارة امتلكت نشاطاً ملحوظاً مضاداً للميكروبات ضد كل من السلالات البكتيرية والفطريات، حيث أظهرت **T3A** و **T5A** و **T7A** أعلى قيم MIC حيث بلغت 1.25 مجم/مل تجاه العصويات الشمعية. أشارت اختبارات التركيز الأدنى للمضاد للبكتيريا إلى أن جميع المركبات قد أظهرت أعلى خاصية للإبادة تجاه الكليسيية الرئوية بتركيز 10.0 مجم/مل. أظهرت نتائج جميع التوليفات بين المضادات الحيوية والمركبات المولفة تأثيراً تناقضياً كبيراً وتأثيرات حيادية، ولكن لوحظت تأثيرات تآزرية في المركبات **T4A** و **T7A** و **T10A** و **T11A** و **T12A** و **T16A** المدججة مع التتراسيكلين مع قيم FICI بلغت 0.2 إلى 0.3 ضد الإشريكية القولونية. كان المركب **T4A** المركب الأكثر نشاطاً مع قدرة إبادة كبيرة تجاه جميع الميكروبات المختبرة لإنتاجه أقل عدد من المستزرعات الناجية بعد 30 دقيقة وذلك في مجال $10^2 \times 43 - 10^2 \times 13$ CFU/مل، يليه المركبين **T5A** و **T7A** في نطاق $10^2 \times 48 - 10^2 \times 17$ و $10^2 \times 51 - 10^2 \times 13$ CFU/مل لكل منهما. أظهر **T4A** أعلى نسبة امتصاص للـ CV ضد الإشريكية القولونية والشيغيلة الفلكسنرية وذلك بنسبة 77.7% و 83.1% على التوالي. أشار تحديد تسرب الأحماض النووية (UV_{260}) والمواد الممتصة للبروتين (UV_{280}) إلى أن **T4A** و **T7A** قد أظهرتا نتائج واعدة بأعلى قيم امتصاص ل OD_{260} عند 1.07 و 0.98 ضد الإشريكية القولونية، بينما تم تسجيل OD_{280} عند 1.00 و 0.98 ضد العصوية الرقيقة بتركيز $4 \times MIC$. تم إخضاع جميع المركبات التي تم توليفها من كلا السلسلتين لاختبارات الإرساء الجزيئي الحاسوبية ضد **GlcN-6-P** باعتباره الإنزيم المستهدف، وأوضحت النتائج قيم هامة لطاقت الربط لكل من **T4A** و **T7A** و **T5A** والتي توافقت مع نتائج النشاط المضاد للميكروبات بنسب -7.73 و -7.32 و -7.31 كيلو كالوري/مول على التوالي.

APPROVAL PAGE

The thesis of Iswatun Hasanah Abdullah Ripain has been approved by the following:

Nurziana Ngah
Supervisor

Deny Susanti Darnis
Co-Supervisor

Noraslinda M Bunnori
Co-Supervisor

Zaimi Azira Zainal Abidin
Internal Examiner

Amir Feisal Merican bin Aljunid Merican
External Examiner

Karimah Kassim
External Examiner

Abdul Razak Kasmuri
Chairman


DECLARATION

I hereby declare that this thesis is the result of my own investigations, except where otherwise stated. I also declare that it has not been previously or concurrently submitted as a whole for any other degrees at IIUM or other institutions.

Iswatun Hasanah binti Abdullah Ripain

Signature

Date



INTERNATIONAL ISLAMIC UNIVERSITY MALAYSIA

**DECLARATION OF COPYRIGHT AND AFFIRMATION OF
FAIR USE OF UNPUBLISHED RESEARCH**

**SYNTHESIS, CHARACTERIZATION, ANTIMICROBIAL AND
MOLECULAR DOCKING STUDIES OF 1,3-THIAZOLE
DERIVATIVES**

I declare that the copyright holders of this thesis are jointly owned by the student and IIUM.

Copyright © 2021 Iswatun Hasanah binti Abdullah Ripain and International Islamic University Malaysia. All rights reserved.

No part of this unpublished research may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise without prior written permission of the copyright holder except as provided below

1. Any material contained in or derived from this unpublished research may be used by others in their writing with due acknowledgement.
2. IIUM or its library will have the right to make and transmit copies (print or electronic) for institutional and academic purposes.
3. The IIUM library will have the right to make, store in a retrieved system and supply copies of this unpublished research if requested by other universities and research libraries.

By signing this form, I acknowledged that I have read and understand the IIUM Intellectual Property Right and Commercialization policy.

Affirmed by Iswatun Hasanah binti Abdullah Ripain

.....
Signature

.....
Date



To Yummy,

*Without your constant love and support, none of this would have been possible. Thank
you so much.*

ACKNOWLEDGEMENTS

Peace upon you and Alhamdulillah to Allah S.W.T., I manage to complete my project within the period given.

First and foremost, I would like to express my countless and utmost gratitude to my helpful supervisor, Associate Professor Dr. Nurziana binti Ngah for her support, patience, advises and supervision in helping me during this tough period to complete this project. Thanks also to my co-supervisors; Associate Professor Dr. Noraslinda Muhamad Bunnori and Associate Professor Dr. Deny Susanti Darnis. The great co-operation from them really helps me in the synthesis and application part for my project and thesis.

I would like to express my sincerest thanks and great appreciations to my beloved husband, Mohd Faizuddin bin Abu Hasan, my cherished parents and in-laws, Abdullah Ripain bin Omar, Robaha binti Abdullah, Abu Hasan bin Wahid, Enche Timah binti Mamat and all my family members that help and encourage me from time to time during the study by gave me all moral and financial support as well as being supportive to me.

My grateful thanks also go to all lab assistants and science officers in Kulliyah of Sciences. A big contribution and hard work from all of you have teaching me so much for completing the project. Your sincere help will be appreciated. All the hardship that we had through together is greatly remembered.

Millions of thanks also go to all my friends for all the cooperation and constant encouragement given to me during this period. Without them, I could not have done until this far. Hope from all the experiences, knowledge and activities that I get during the project will give me an opportunity and benefit to me in future.

Last but not least, to those who directly and indirectly involved in this research, a sincere thanks from me. May Allah bless you with happiness and success. Thank you.

TABLE OF CONTENTS

Abstract	ii
Abstract in Arabic	iii
Approval Page.....	iv
Declaration.....	v
Copyright Page.....	vi
Acknowledgements.....	viii
Table of Contents.....	ix
List of Tables	xii
List of Figures	xiii
List of Schemes.....	xviii
List of Symbols.....	xxi
List of Abbreviations	xxiii
Compounds Numbering Scheme of Synthesized Thiazole Derivatives	xxiv
CHAPTER ONE: INTRODUCTION	1
1.1 Research Background	1
1.2 Problem Statements	4
1.3 Hypothesis of The Study	5
1.4 The Aims of Study.....	6
1.5 Research Outline.....	6
CHAPTER TWO: LITERATURE REVIEW.....	8
2.1 Chemistry of Thiazole	8
2.1.1 Synthetic Approach of Thiazole Derivatives	10
2.2 Industrial Application of Thiazole Derivatives	15
2.3 Biological and Pharmacological Applications of Thiazole Derivatives.....	21
2.3.1 Anticancer Activity of Thiazole Derivatives	21
2.3.2 Anti-Inflammatory Activity of Thiazole Derivatives	23
2.3.3 Antioxidant Activity of Thiazole Derivatives.....	26
2.3.4 Antimicrobial Activity of Thiazole Derivatives	26
2.4 Antibiotics	31
2.5 Antimicrobial Evaluation	34
2.6 Molecular Docking Studies	37
2.6.1 Molecular Docking in Antimicrobial Studies	39
2.7 Glucosamine-6-Phosphate Synthase (GlcN-6-P)	43
2.7.1 Inhibition of GlcN-6-P Synthase.....	46
CHAPTER THREE: SYNTHESIS AND CHARACTERIZATION OF 1,3-THIAZOLE DERIVATIVES	49
3.1 Chemicals and Materials.....	49
3.2 Instrumentation.....	50
3.3 Experiment.....	51
3.3.1 Synthesis of Series A (T1A-T17A).....	52
3.3.2 Synthesis of Series B (T1B-T17B)	69

3.4 Results and Discussion	85
3.4.1 Synthesis of 2, 4, 5-Trisubstituted-1,3-Thiazole Derivatives	85
3.4.2 Physical Properties	87
3.4.3 Solubility Test	90
3.4.4 Infrared Spectroscopy Analysis	92
3.4.5 Proton NMR Analysis (¹ H NMR)	94
3.4.6 Carbon NMR Analysis (¹³ C NMR)	99
3.4.7 UV Spectra Analysis	103
3.4.8 Electron Ionization-Mass Spectrometry (EI-MS) Analysis	109
CHAPTER FOUR: ANTIMICROBIAL ACTIVITIES	116
4.1 Introduction	116
4.2 Antimicrobial Studies	116
4.3 Materials and Methods	117
4.3.1 Test Microorganisms	117
4.3.2 Preparation of Inoculum	117
4.3.3 Disc Diffusion Assay	118
4.3.4 Minimum Inhibition Concentration (MIC) Test	118
4.3.5 Minimum Bactericidal/Fungicidal Concentration (MBC/MFC) Test	119
4.3.6 Synergistic Effect Determination	120
4.3.7 Salt Tolerance Assay	120
4.3.8 Time-Killing Assay	121
4.3.9 Crystal Violet Assay	121
4.3.10 Leakage of 260 and 280 nm-Absorbing Material Assay	122
4.4 Results and Discussion	123
4.4.1 Disc Diffusion Assay	123
4.4.2 Minimum Inhibition Concentration (MIC) and Minimum Bactericidal/Fungicidal Concentration (MFC/MBC) Assays	128
4.4.3 Synergistic Effect Determination	133
4.4.4 Salt Tolerance Assay	139
4.4.5 Time-Killing Assay	146
4.4.6 Crystal Violet Assay	151
4.4.7 Leakage of 260/280 nm-Absorbing Material Assay	157
CHAPTER FIVE: MOLECULAR DOCKING STUDIES	169
5.1 Introduction	169
5.2 Methods	170
5.2.1 Multiple Sequence Alignment (MSA) Preparation	170
5.2.2 Protein Secondary Structure Preparation	171
5.2.3 Molecular Docking Analysis	171
5.3 Results and Discussions	173
5.3.1 Multiple Sequence Alignment (MSA) Analysis	173
5.3.2 Protein Secondary Structure Analysis	175
5.3.3 Molecular Docking Analysis	177
5.4 Conclusion	196

CHAPTER SIX: CONCLUSION AND FUTURE WORKS	197
6.1 Conclusion	197
6.2 Future Works	199
REFERENCES.....	201
APPENDIX A: INFRARED SPECTRA	230
APPENDIX B: ¹H-NMR SPECTRA	231
APPENDIX C: ¹³C-NMR SPECTRA.....	232
APPENDIX D: UV ABSORPTION SPECTRA	233
APPENDIX E: MASS SPECTRA	234
APPENDIX F-K: MOLECULAR DOCKING.....	235
APPENDIX L: PUBLICATIONS	236



LIST OF TABLES

<u>Table No.</u>		<u>Page No.</u>
2.1	Some Examples of Different Types of Synthesized Thiazole and Their Applications	20
2.2	Inhibition Activity of 4-(4-Substituted Phenyl)-2-(Amino-1-yl) Thiazol-5-yl)(Phenyl) Methanone Derivatives (52-54) and Standard Drug (Sinha, Doble & Manju, 2018)	25
2.3	Example of Bioactive Compounds and Their Activities	33
2.4	Molecular Docking Studies of Thiazole Derivatives Against Selected Enzyme	42
3.1	List of Chemicals and Solvents	49
3.2	Physical Properties of Thiazole Derivatives of Series A and B	88
3.3	List of Solubility Test for Synthesized Thiazole Derivatives	90
4.1	Antimicrobial Activity of Synthesized Thiazole Derivatives for Series A and Series B	124
4.2	MICs and MBCs/MFCs of the Selected Synthesized Thiazole Derivatives (mg/mL)	129
4.3	Fractional Inhibitory Concentration Index (FICI) Combination of the Synthesized Compounds and Streptomycin	135
4.4	Fractional Inhibitory Concentration Index (FICI) Combination of Synthesized Compounds and Tetracycline	136
4.5	Fractional Inhibitory Concentration Index (FICI) Combination of Synthesized Compounds and Clotrimazole	137
5.1	<i>In silico</i> Molecular Docking Results of the Synthesized Compounds and Standard Drugs Towards GlcN-6-P Synthase	181

LIST OF FIGURES

<u>Figure No.</u>		<u>Page No.</u>
1.1	Structure of Thiazole Derivatives	3
2.1	General Structure of Thiazole Compound	8
2.2	Resonance Forms of Thiazole Compound	9
2.3	Molecular Structure of Commercialized Thiamethoxam	16
2.4	Molecular Structures of Thiazolothiazole based Copolymers as Semiconductors	16
2.5	Molecular Structure of PCDTTz as Organic Semiconductor	17
2.6	Molecular Structure of <i>N</i> ⁴ -(5-Methylthiazole-2-yl)-1,3-Thiazole-2,4-Diamine as Disperse Dyes (Malik <i>et al.</i> , 2014)	18
2.7	Molecular Structure of 2-Amino-4-Arylazo-Thiazole Disperse Dyes (Gaffer, Fouda & Khalifa, 2016)	18
2.8	Molecular Structure of Combretastatin as Anticancer Candidate (Romagnoli <i>et al.</i> , 2012)	21
2.9	Molecular Structure of Antitumor Candidates Containing Thiazole Moiety (Yuan <i>et al.</i> , 2014)	22
2.10	Structure of 1,3-Thiazole Derivative as Antitumor Candidate (He <i>et al.</i> , 2016)	23
2.11	Chemical Structure of 2-Aminothiazole Derivatives as Anti-Inflammatory (Khalifa, 2018)	23
2.12	The Structures of Antioxidant Agents of 55 , 56 and 57 Synthesized by Djukic <i>et al.</i> , (2018)	26
2.13	The Structures of 2-(4-Hydroxyphenyl) Benzo[<i>d</i>]thiazole (58) and 2-(3-Hydroxyphenyl) Benzo[<i>d</i>]thiazole (59)	28
2.14	Series of 2,4-Disubstituted Thiazole Derivatives as Antimicrobial Agents (Arora <i>et al.</i> , 2015)	29
2.15	Newly Synthesized (2-Aminothiazol-4-yl) Methylene Derivatives as Antibacterial and Antifungal Agents (Karuvalam <i>et al.</i> , 2012)	30

2.16	Molecular Structures of Fluorinated Benzothiazole-2-yl-1,2,4-Triazoles Derivatives Prepared by Sidhu & Kukreja (2015)	31
2.17	Docking Structure of Compound 81 into the Binding Pocket of LDH-5 Synthase (Gomha <i>et al.</i> , 2016)	40
2.18	Molecular Structure of Benzo[d]thiazole Hydrazones Derivatives as Potential Antifungal Agents (Zha <i>et al.</i> , 2017)	41
2.19	Structure of Bacterial Glucosamine-6-Phosphate Synthase Downloaded from www.rcsb.org (Berman <i>et al.</i> , 2000)	45
3.1	The Infrared Spectrum of 5-Acetyl-4-Methyl-2-(4-Methylaniline)-1,3-Thiazole (T2A)	93
3.2	¹ H-NMR Spectrum of 5-Acetyl-4-Methyl-2-(3,4-Dichloroaniline)-1,3-Thiazole (T14A) (Series A)	96
3.3	¹ H-NMR Spectrum of 2-(3,4-Dichloroaniline)-4,5-Dimethyl-1,3-Thiazole (T14B) (Series B)	98
3.4	¹³ C NMR Spectrum of 5-Acetyl-4-Methyl-2-(3,4-Dichloroaniline)-1,3-Thiazole (T14A) as Representative for Series A	100
3.5	¹³ C NMR Spectrum of 2-(3,4-Dichloroaniline)-4,5-Dimethyl-1,3-Thiazole (T14B) as Representative for Series B	102
3.6	UV Spectrum of 5-Acetyl-4-Methyl-2-(4-Vinylaniline)-1,3-Thiazole (T4A) as Representative of Series A	105
3.7	UV Spectrum of 2-(4-Vinylaniline)-4,5-Dimethyl-1,3-Thiazole (T4B) as Representative of Series B	108
3.8	Mass Spectrum of 5-Acetyl-4-Methyl-2-(4-Methylaniline)-1,3-Thiazole (T2A)	110
3.9	Mass Spectrum of 5-Acetyl-4-Methyl-2-(4-Chloroaniline)-1,3-Thiazole (T13A)	112
3.10	Mass Spectrum of 5-Acetyl-4-Methyl-2-(3,4-Dichloroaniline)-1,3-Thiazole (T14A)	114
3.11	Mass Spectrum of 2-(4-Dichloroaniline)-4,5-Dimethyl-1,3-Thiazole (T14B)	115

4.1	Salt Tolerances by Untreated (Control) and Treated Microbial Strains at Concentration equal to MIC and 2× MIC of Synthesized Compounds: (a) <i>B. cereus</i> ; (b) <i>B. subtilis</i> ; (c) <i>S. aureus</i> ; (d) <i>S. epidermidis</i> ; (e) <i>E. coli</i> ; (f) <i>P. aeruginosa</i> ; (g) <i>S. flexneri</i> ; (h) <i>S. typhimurium</i> ; (i) <i>K. pneumoniae</i> ; and (j) <i>C. albicans</i>	143
4.2	Time-Killing Curves of Microbial Strains at Concentrations of 4 × MIC: (a) <i>B. cereus</i> ; (b) <i>B. subtilis</i> ; (c) <i>S. aureus</i> ; (d) <i>S. epidermidis</i> ; (e) <i>E. coli</i> ; (f) <i>P. aeruginosa</i> ; (g) <i>S. flexneri</i> ; (h) <i>S. typhimurium</i> ; (i) <i>K. pneumoniae</i> ; and (j) <i>C. albicans</i>	147
4.3	Percent of Crystal Violet Uptake by Untreated and Treated Microbial Strains at Concentration Equal to 2 × MIC and 4 × MIC of Synthesized Compounds, 0.25M EDTA and Standard Drugs: (a) <i>B. cereus</i> ; (b) <i>B. subtilis</i> ; (c) <i>S. aureus</i> ; (d) <i>S. epidermidis</i> ; (e) <i>E. coli</i> ; (f) <i>P. aeruginosa</i> ; (g) <i>S. flexneri</i> ; (h) <i>S. typhimurium</i> ; (i) <i>K. pneumoniae</i> ; and (j) <i>C. albicans</i>	152
4.4	Leakage of Extracellular 260nm-Absorbing Materials from Untreated and Treated Microbial Strains with Compounds and Standard Drugs at Concentration Equal to 2 × MIC and 4 × MIC: (a) <i>B. cereus</i> ; (b) <i>B. subtilis</i> ; (c) <i>S. aureus</i> ; (d) <i>S. epidermidis</i> ; (e) <i>E. coli</i> ; (f) <i>P. aeruginosa</i> ; (g) <i>S. flexneri</i> ; (h) <i>S. typhimurium</i> ; (i) <i>K. pneumoniae</i> ; and (j) <i>C. albicans</i>	158
4.5	Leakage of 280 nm-Absorbing Materials from Untreated and Treated Ten Microbial Strains with Compounds and Standard Drugs at Concentration Equal to 2×MIC and 4×MIC: (a) <i>B. cereus</i> ; (b) <i>B. subtilis</i> ; (c) <i>S. aureus</i> ; (d) <i>S. epidermidis</i> ; (e) <i>E. coli</i> ; (f) <i>P. aeruginosa</i> ; (g) <i>S. flexneri</i> ; (h) <i>S. typhimurium</i> ; (i) <i>K. pneumoniae</i> ; and (j) <i>C. albicans</i>	163
5.1	Multiple Alignment Structure (MSA) of GlcN-6-P Synthase in Biological Sequences of Human and Ten Other Microorganisms	174
5.2	Secondary Structure Prediction of Glucosamine-6-Phosphate Synthase Retrieved from https://www.rcsb.org/structure/1MOQ	176
5.3	The Binding of the Best Generated Conformers of Series A (T3A , T4A , T5A and T7A) inside the Binding Pocket of Target Enzyme	178
5.4	The Binding of the Best Generated Conformers of Series B (T3B , T4B , T5B and T7B) inside the Binding Pocket of Target Enzyme	179

5.5	The Molecular Interactions of Thiazole Derivative (Ligand) of 5-Acetyl-4-Methyl-2-(4-Ethylaniline)-1,3-Thiazole (T3A) of Series A with GlcN-6-P Synthase with 3D and 2D Views	187
5.6	Figure 5.6 The Molecular Interactions of Thiazole Derivative (Ligand) of 5-Acetyl-4-Methyl-2-(4-Vinylaniline)-1,3-Thiazole (T4A) of Series A with GlcN-6-P Synthase with 3D and 2D views	187
5.7	The Molecular Interactions of Thiazole Derivative (Ligand) of 5-Acetyl-4-Methyl-2-(4-Isopropylaniline)-1,3-Thiazole (T5A) of Series A with GlcN-6-P Synthase with 3D and 2D Views	188
5.8	The molecular Interactions of Thiazole Derivative (Ligand) of 5-Acetyl-4-Methyl-2-(4-Aminobiphenyl)-1,3-Thiazole (T7A) of Series A with GlcN-6-P Synthase with 3D and 2D Views	188
5.9	The Molecular Interactions of Thiazole Derivative (Ligand) of 2-(4-Ethylaniline)-4,5-Dimethyl-1,3-Thiazole (T3B) of Series B with GlcN-6-P Synthase with 3D and 2D Views	189
5.10	The Molecular Interactions of Thiazole Derivative (Ligand) of 2-(4-Vinylaniline)-4,5-Dimethyl-1,3-Thiazole (T4B) of Series B with GlcN-6-P Synthase with 3D and 2D Views	189
5.11	The Molecular Interactions of Thiazole Derivative (Ligand) of 2-(4-Isopropylaniline)-4,5-Dimethyl-1,3-Thiazole (T5B) of Series B with GlcN-6-P Synthase with 3D and 2D Views	190
5.12	The Molecular Interactions of Thiazole Derivative (Ligand) of 2-(4-Aminobiphenyl)-4,5-Dimethyl-1,3-Thiazole (T7B) of Series B with GlcN-6-P Synthase with 3D and 2D Views	190
5.13	The Molecular Interactions of Standard Drugs Namely Streptomycin with GlcN-6-P Synthase with 3D and 2D Views	194
5.14	The Molecular Interactions of Standard Drugs Namely Tetracycline with GlcN-6-P Synthase with 3D and 2D Views	194
5.15	The Molecular Interactions of Standard Drugs Namely Clotrimazole with GlcN-6-P Synthase with 3D and 2D Views	195

5.16 The Molecular Interactions of Initial Ligand Namely 2-(*N*-Morpholino)-Ethanesulfonic Acid with GlcN-6-P Synthase with 3D and 2D Views

195



LIST OF SCHEMES

<u>Scheme No.</u>		<u>Page No.</u>
2.1	Reaction Synthesis of 2-(3-Pyridyl) Thiazole Derivatives According to Bondock, Naser & Ammar (2013)	11
2.2	Hantzsch Type Synthesis of 2,4-Diphenyl-5-(1,1,2,2-Tetrafluoroethoxy)-Thiazole (16) (Sokolenko, Davydova & Yagupolskii (2012))	11
2.3	The Cook-Heilbron Thiazole Synthesis (Frija <i>et al.</i> , 2016)	12
2.4	Synthesis of Thiazole Compound <i>via</i> Gabriel Reaction (Kotadiya, 2017)	13
2.5	One-Pot Multicomponent Synthesis of Thiazole Derivatives by Using Derived Enzyme (Zheng <i>et al.</i> , 2013)	14
2.6	Reaction Involved in the Synthesis of Thiazole Compound as Anti-Inflammatory Agent (Fatima, Kulkarni & Mantipragada, 2015)	14
2.7	Reaction Catalysed by Glucosamine-6-Phosphate Synthase (GlcN-6-P)	45
3.1	The General Synthesis of 2, 4, 5-Trisubstituted-1,3-Thiazole Derivatives	52
3.2	Synthetic Approach Adopted in this Study Featuring 5-Acetyl-4-Methyl-2-Methylamine-1,3-Thiazole (T1A)	52
3.3	Synthetic Approach Adopted in this Study Featuring 5-Acetyl-4-Methyl-2-(4-Methylaniline)-1,3-Thiazole (T2A)	53
3.4	Synthetic Approach Adopted in this Study Featuring 5-Acetyl-4-Methyl-2-(4-Ethylaniline)-1,3-Thiazole (T3A)	54
3.5	Synthetic Approach Adopted in this Study Featuring 5-Acetyl-4-Methyl-2-(4-Vinylniline)-1,3-Thiazole (T4A)	55
3.6	Synthetic Approach Adopted in this Study Featuring 5-Acetyl-4-Methyl-2-(4-Isopropylaniline)-1,3-Thiazole (T5A)	56

3.7	Synthetic Approach Adopted in this Study Featuring 5-Acetyl-4-Methyl-2-(4-Tertbutylaniline)-1,3-Thiazole (T6A)	57
3.8	Synthetic Approach Adopted in this Study Featuring 5-Acetyl-4-Methyl-2-(4-Aminobiphenyl)-1,3-Thiazole (T7A)	58
3.9	Synthetic Approach Adopted in this Study Featuring 5-Acetyl-4-Methyl-2-(4-Aminophenol)-1,3-Thiazole (T8A)	59
3.10	Synthetic Approach Adopted in this Study Featuring 5-Acetyl-4-Methyl-2-(4-Methoxyaniline)-1,3-Thiazole (T9A)	60
3.11	Synthetic Approach Adopted in this Study Featuring 5-Acetyl-4-Methyl-2-(4-Propoxyaniline)-1,3-Thiazole (T10A)	61
3.12	Synthetic Approach Adopted in this Study Featuring 5-Acetyl-4-Methyl-2-(Methyl-4-Aminobenzoate)-1,3-Thiazole (T11A)	62
3.13	Synthetic Approach Adopted in this Study Featuring 5-Acetyl-4-Methyl-2-(Ethyl-4-Aminobenzoate)-1,3-Thiazole (T12A)	63
3.14	Synthetic Approach Adopted in this Study Featuring 5-Acetyl-4-Methyl-2-(4-Chloroaniline)-1,3-Thiazole (T13A)	64
3.15	Synthetic Approach Adopted in this Study Featuring 5-Acetyl-4-Methyl-2-(3,4-Dichloroaniline)-1,3-Thiazole (T14A)	65
3.16	Synthetic Approach Adopted in this Study Featuring 5-Acetyl-4-Methyl-2-(2-Methylthioaniline)-1,3-Thiazole (T15A)	66
3.17	Synthetic Approach Adopted in this Study Featuring 5-Acetyl-4-Methyl-2-(4-Methylthioaniline)-1,3-Thiazole (T16A)	67
3.18	Synthetic Approach Adopted in this Study Featuring 5-Acetyl-2-Aniline-4-Methyl-1,3-Thiazole (T17A)	68
3.19	Synthetic Approach Adopted in this Study Featuring 2-Methylamine-4,5-Dimethyl-1,3-Thiazole (T1B)	69
3.20	Synthetic Approach Adopted in this Study Featuring 2-(4-Methylaniline)-4,5-Dimethyl-1,3-Thiazole (T2B)	70

3.21	Synthetic Approach Adopted in this Study Featuring 2-(4-Ethylaniline)-4,5-Dimethyl-1,3-Thiazole (T3B)	71
3.22	Synthetic Approach Adopted in this Study Featuring 2-(4-Vinylaniline)-4,5-Dimethyl-1,3-Thiazole (T4B)	72
3.23	Synthetic Approach Adopted in this Study Featuring 2-(4-isopropylaniline)-4,5-Dimethyl-1,3-Thiazole (T5B)	73
3.24	Synthetic Approach Adopted in this Study Featuring 2-(4-Terbutylaniline)-4,5-Dimethyl-1,3-Thiazole (T6B)	74
3.25	Synthetic Approach Adopted in this Study Featuring 2-(4-Aminobiphenyl)-4,5-Dimethyl-1,3-Thiazole (T7B)	75
3.26	Synthetic Approach Adopted in this Study Featuring 2-(4-Aminophenol)-4,5-Dimethyl-1,3-Thiazole (T8B)	76
3.27	Synthetic Approach Adopted in this Study Featuring 2-(4-Methoxyaniline)-4,5-Dimethyl-1,3-Thiazole (T9B)	77
3.28	Synthetic Approach Adopted in this Study Featuring 2-(4-Propoxyaniline)-4,5-Dimethyl-1,3-Thiazole (T10B)	78
3.29	Scheme 3.29 Synthetic Approach Adopted in this Study Featuring 2-(Methyl-4-Aminobenzoate)-4,5-Dimethyl-1,3-Thiazole (T11B)	79
3.30	Synthetic Approach Adopted in this Study Featuring 2-(Ethyl-4-Aminobenzoate)-4,5-Dimethyl-1,3-Thiazole (T12B)	80
3.31	Synthetic Approach Adopted in this Study featuring 2-(4-Chloroaniline)-4,5-Dimethyl-1,3-Thiazole (T13B)	81
3.32	Synthetic Approach Adopted in this Study Featuring 2-(3,4-Dichloroaniline)-4,5-Dimethyl-1,3-Thiazole (T14B)	82
3.33	Synthetic Approach Adopted in this Study Featuring 2-(2-Methylthioaniline)-4,5-Dimethyl-1,3-Thiazole (T15B)	83
3.34	Synthetic Approach Adopted in this Study Featuring 2-(4-Methylthioaniline)-4,5-Dimethyl-1,3-Thiazole (T16B)	84
3.35	Synthetic Approach Adopted in this Study Featuring 2-Aniline-4,5-Dimethyl-1,3-Thiazole (T17B)	85
3.36	Proposed Mechanism for the Synthesis of Thiazole Compounds	86

LIST OF SYMBOLS

α	Alpha
δ	Chemical shift
ν	Frequency
$^{\circ}\text{C}$	Degree Celcius
$^{\circ}$	Degree
eV	Electronvolt
ϵ	Extinction Coefficient
%	Percent
π	pi
λ	Wavelength
\AA	angstrom
ca.	circa
cm	centimeter
cm^{-1}	Wavenumbers (reciprocal centimeters)
g	gram
Hz	Hertz
J_{HH}	Proton Coupling Constant
kcal/mol	Kilocalories per mole
kJ/mol	KiloJoules per mole
K_i	Inhibition constant
Log P	Partition Coefficient
m	Medium







m	Multiplet
mm	Milimeter
m/z	Mass
M	Molarity
MHz	Mega Hertz
$M^{-1}cm^{-1}$	Molar absorptivity
mg	Milligram
min	Minute
mmol	Milimole
mL	Mililiter
nm	Nanometre
μg	Microgram
μL	Microliter
μM	Micrometre

LIST OF ABBREVIATIONS

Abs	Absorbance	KBr	Potassium bromide
CDCl ₃	Deuterated Chloroform	LUMO	Lowest Unoccupied Molecular Orbital
CFU	Colony-forming unit	ppm	Part per million
DMSO-d ₆	Deuterated Dimethyl sulfoxide	NMR	Nuclear Magnetic Resonance
d	Doublet	pseudo-d	Pseudo doublet
EDTA	Ethylenediamine tetraacetic acid	s	Singlet
<i>et al</i>	and others (in Latin)	s	Strong
FTIR	Fourier Transform Infrared	sp	Species
HCl	Hydrochloric acid	t	Triplet
HOMO	Highest Occupied Molecular Orbital	TMS	Tetramethylsilane
IC ₅₀	Half maximal inhibitory concentration	UV-vis	Ultraviolet-visible
IR	Infrared	w	weak

COMPOUNDS NUMBERING SCHEME OF SYNTHESIZED THIAZOLE DERIVATIVES

SERIES A (5-ACETYL-4-METHYL-1,3-THIAZOLE)

NO.	MOLECULAR STRUCTURE	MOLECULAR FORMULA	NOVELTY
T1A	 <p>5-acetyl-4-methyl-2-methylamine-1,3-thiazole</p>	C ₇ H ₁₀ N ₂ OS	X
T2A	 <p>5-acetyl-4-methyl-2-(4-methylaniline)-1,3-thiazole</p>	C ₁₃ H ₁₄ N ₂ OS	X
T3A	 <p>5-acetyl-4-methyl-2-(4-ethylaniline)-1,3-thiazole</p>	C ₁₄ H ₁₆ N ₂ OS	/
T4A	 <p>5-acetyl-4-methyl-2-(4-vinylaniline)-1,3-thiazole</p>	C ₁₄ H ₁₄ N ₂ OS	/
T5A	 <p>5-acetyl-4-methyl-2-(4-isopropylaniline)-1,3-thiazole</p>	C ₁₅ H ₁₈ N ₂ OS	/
T6A	 <p>5-acetyl-4-methyl-2-(4-tertbutylaniline)-1,3-thiazole</p>	C ₁₆ H ₂₀ N ₂ OS	X